ArticleCancer2010

Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.

Suresh S Ramalingam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.